Search

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Highlights from the SWG

SWG Committee meetingsIn 2023, the SWG Committee held meetings on:

February 21, 2023—online
April 6, 2023—in The Hague
June 8, 2023—at the EHA Congress 2023 in Frankfurt
In addition, an SWG Chairs and Committee Meeting was held on September 29, 2023, in The Hague.…

Read more

SWG Grant-funded projects, 2024

In November and December of 2023, SWGs were invited to develop project ideas and apply for a 2024 SWG Grant. ApplicationsWe received 11 different applications from 9 SWGs. This was two more applications than we received in 2022.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy

Dates: November 23-25, 2017
Location: Amsterdam, The Netherlands
Chair: WE Fibbe, F Dazzi

Organized by:

EHA and the EHA Scientific Working Group on Mesenchymal Stromal Cells

The SWG Meeting “Shaping the future of MSC therapy” brought together basic science, as well as translational and clinical research.…

Read more